PROSCILLARIDIN

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C30H42O8
Molecular Weight	530.6497
Optical Activity	UNSPECIFIED
Defined Stereocenters	12 / 12
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

C[C@@H]1O[C@@H](O[C@H]2CC[C@]3(C)[C@H]4CC[C@]5(C)[C@H](CC[C@]5(O)[C@@H]4CCC3=C2)C6=COC(=O)C=C6)[C@H](O)[C@H](O)[C@H]1O

InChI

InChIKey=MYEJFUXQJGHEQK-ALRJYLEOSA-N

InChI=1S/C30H42O8/c1-16-24(32)25(33)26(34)27(37-16)38-19-8-11-28(2)18(14-19)5-6-22-21(28)9-12-29(3)20(10-13-30(22,29)35)17-4-7-23(31)36-15-17/h4,7,14-16,19-22,24-27,32-35H,5-6,8-13H2,1-3H3/t16-,19-,20+,21-,22+,24-,25+,26+,27-,28-,29+,30-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C30H42O8
Molecular Weight	530.6497
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	12 / 12
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.google.si/patents/US20060135468
Curator's Comment: description was created based on several sources, including, http://www.ijppsjournal.com/Vol5Issue4/7570.pdf, http://www.ptfarm.pl/pub/File/Acta_Poloniae/2005/4/319.pdf

Proscillaridin is a substance that was used in Europe for the treatment of heart failure and atrial fibrillation. Proscillaridin belongs to glycosides and acts as a Na /K -ATPase inhibitor.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium/potassium-transporting ATPase 34 Target ID: CHEMBL2095186 Sources: http://www.ptfarm.pl/pub/File/Acta_Poloniae/2005/4/319.pdf	Inhibitor 8504		0.17 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Chronic cardiac insufficiency 1 Sources: http://www.ptfarm.pl/pub/File/Acta_Poloniae/2005/4/319.pdf	Primary		Approved 8583	TALUSIN Approved Use Unknown
Atrial fibrillation 131 Sources: http://www.ptfarm.pl/pub/File/Acta_Poloniae/2005/4/319.pdf	Primary		Approved 8583	TALUSIN Approved Use Unknown

PubMed

Title	Date	PubMed
Inhibition of DNA topoisomerases I and II by G3 PAMAM-NH2 dendrimer-modified digoxin and proscillaridin A conjugates in a cell free system.	2011-01-15	21229879
Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents.	2010-09-27	20885994
Dual effects of ouabain, digoxin and proscillaridin A on the regulation of apoptosis in human fibroblasts.	2010-02	20140806
Cardiac glycosides induce cell death in human cells by inhibiting general protein synthesis.	2009-12-16	20016840
Cytotoxic effects of cardiac glycosides in colon cancer cells, alone and in combination with standard chemotherapeutic drugs.	2009-11	19894733
Synthesis and cytotoxic activity of G3 PAMAM-NH(2) dendrimer-modified digoxin and proscillaridin A conjugates in breast cancer cells.	2009-07-07	20508299
Antiproliferative activity of derivatives of ouabain, digoxin and proscillaridin A in human MCF-7 and MDA-MB-231 breast cancer cells.	2008-06	18520043
Apoptosis-mediated cytotoxicity of ouabain, digoxin and proscillaridin A in the estrogen independent MDA-MB-231 breast cancer cells.	2007-10	18038900
Combinatorial computational approaches to identify tetracycline derivatives as flavivirus inhibitors.	2007-05-09	17502914
Inhibition of DNA topoisomerases I and II, and growth inhibition of breast cancer MCF-7 cells by ouabain, digoxin and proscillaridin A.	2006-07	16819197
A novel endogenous digitalis, telocinobufagin, exhibits elevated plasma levels in patients with terminal renal failure.	2005-01	15607315
[Separation and purification of an endogenous inhibitor of sodium pump from chansu by thin-layer chromatography and reversed-phase high performance liquid chromatography].	2001-11	12545474
[An elderly case of idiopathic dilatation of the right atrium in which right-sided heart failure was exacerbated by drug-induced bradyarrhythmia].	2001-07	11523170
Cytotoxicity of digitoxin and related cardiac glycosides in human tumor cells.	2001-06	11395576
Exquisitely small amounts of nonglucocorticoid natural steroids suppress the human allogeneic T-cell response.	2001-03-27	11266951
Sanguinarine induces K+ outflow from yeast cells expressing mammalian sodium pumps.	2001-02	11218072
The T-cell suppressive effect of bufadienolides: structural requirements for their immunoregulatory activity.	2001-01	11367509

Patents

Sample Use Guides

In Vivo Use Guide

The typical dose for current indication (p.o.) is about 1.5 mg/day.

Route of Administration: Oral

In Vitro Use Guide

Aggregation of platelets, preincubated 20 min with 100 uM and 200 uM proscillaridin was studied in vitro. Proscillaridin induced, in adose and time dependent manner, aprocoagulant response in platelets. Maximal procoagulant response was observed at 100 uM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:54:40 GMT 2025` Edited by `admin` on `Mon Mar 31 17:54:40 GMT 2025`
Record UNII	KC6BL281EN
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

TALUSIN

Preferred Name

English

PROSCILLARIDIN

Official Name

English

PROSCILLARIDIN [MI]

Common Name

English

NSC-7521

Code

English

proscillaridin [INN]

Common Name

English

Proscillaridin [WHO-DD]

Common Name

English

PROSCILLARIDIN [MART.]

Common Name

English

PROSCILLARIDIN [USAN]

Common Name

English

BUFA-4,20,22-TRIENOLIDE, 3-((6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)OXY)-14-HYDROXY-, (3.BETA.)-

Common Name

English

A-32686

Code

English

PROSCILLARIDIN [JAN]

Common Name

English

Proscillaridin A

Common Name

English

((6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)OXY)-14-HYDROXYBUFA-4,20,22-TRIENOLIDE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C78322